The bill amends Minnesota Statutes 2024, section 152.126, to update the terminology used in the prescription monitoring program, changing "controlled substances" to "reportable substances." This change broadens the definition to include specific drugs like butalbital and FDA-approved opioid antagonists for overdose reversal. The amendments clarify the responsibilities of dispensers and prescribers, indicating that dispensers are not required to report certain prescriptions under specific circumstances, such as for patients in healthcare facilities or those receiving drug samples. Additionally, the bill outlines the requirements for the electronic reporting system, including data submission timelines and the protection of individual identities through encryption.

Furthermore, the bill establishes stricter access and management protocols for data related to opioid prescriptions. It mandates that the Minnesota State Board of Pharmacy will not release data without satisfactory evidence of entitlement from the requester and requires the board to maintain a log of all data access for at least three years. The bill also allows participation in an interstate prescription monitoring program, with access restricted to permissible users. Notably, it introduces a provision that allows patients to request information about who accessed their data, necessitating a notarized request form. Overall, the amendments aim to enhance the efficiency of the prescription monitoring program while ensuring patient privacy and safety.

Statutes affected:
Introduction: 152.126